# Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00006215** · PHASE2 · UNKNOWN · sponsor: **Amgen**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** docetaxel
- **DRUG:** vinorelbine tartrate

## Key facts

- **NCT ID:** NCT00006215
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006215, "Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00006215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*